Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Close
Search
Search
Generics Bulletin
HBW Insight
In Vivo
Medtech Insight
Pink Sheet
Scrip
Patient Preference Data: Pfizer’s Tanezumab Study Had ‘Flaws’ That Made It ‘Uninformative’
Mar 26 2021
•
By
Sue Sutter
Osteoarthritis patients in Pfizer's study said they were more willing to risk joint damage than dependence on opioids. • Source: Shutterstock
More from US FDA Performance Tracker
More from Regulatory Trackers